Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
Open Access
- 11 May 2006
- journal article
- case report
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 129
Abstract
Bortezomib (Velcade), a dipeptide boronate proteasome inhibitor, is a novel anti-cancer agent registered for multiple myeloma (MM). It has also shown promising clinical activity in non-small cell lung cancer (NSCLC). Clinical experience with bortezomib so far indicates that overall incidence of cardiac failure associated with bortezomib therapy remains incidental. Nevertheless, acute development or exacerbation of congestive cardiac failure has been associated with bortezomib treatment. We present here a case of severe, but reversible, congestive cardiac failure in a lung cancer patient who had no prior cardiac history, after receiving an experimental treatment of bortezomib combined with chemotherapy. Elevated levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), as retrospectively measured in archived serum samples, were suggestive of pre-existent (sub-clinical) left ventricular dysfunction. Based on literature, we hypothesize that baseline presence of sub clinical cardiomyopathy, characterized by a dysregulation of the ubiquitin-proteasome system, could have predisposed this patient for a cardiac side effect induced by systemic proteasome inhibition. Patients with heart disease or risk factors for it should be closely monitored when being submitted to treatment with proteasome inhibition therapy such as bortezomib. Caution is therefore warranted in lung cancer patients who often present with cardiac comorbidities.Keywords
This publication has 18 references indexed in Scilit:
- A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid TumorsClinical Cancer Research, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- N-Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunctionClinical Research in Cardiology, 2005
- N-Terminal Pro–B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart DiseaseNew England Journal of Medicine, 2005
- Gene expression changes associated with fibronectin-induced cardiac myocyte hypertrophyPhysiological Genomics, 2004
- The proteasome: a suitable antineoplastic targetNature Reviews Cancer, 2004
- Cardiotoxicity of cytotoxic drugsCancer Treatment Reviews, 2004
- The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extendedCardiovascular Research, 2004
- Hyperubiquitination of proteins in dilated cardiomyopathyProteomics, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000